PARTNERSHIP OPPORTUNITIES
Free Shipping in the U.S. for orders over $1000. Shop Now>>
Analysis of Protein Array containing more than 19,000 full-length human proteins using p120 Mouse Monoclonal Antibody (CTNND1/4207).Z- and S- Score: The Z-score represents the strength of a signal that a monoclonal antibody (MAb) (in combination with a fluorescently-tagged anti-IgG secondary antibody) produces when binding to a particular protein on the HuProtTM array. Z-scores are described in units of standard deviations (SD's) above the mean value of all signals generated on that array. If targets on HuProtTM are arranged in descending order of the Z-score, the S-score is the difference (also in units of SD's) between the Z-score. S-score therefore represents the relative target specificity of a MAb to its intended target. A MAb is considered to specific to its intended target, if the MAb has an S-score of at least 2.5. For example, if a MAb binds to protein X with a Z-score of 43 and to protein Y with a Z-score of 14, then the S-score for the binding of that MAb to protein X is equal to 29.
Alpha-catenin and beta-catenin bind to the intracellular domain of E-cadherin while p120 catenin binds E-cadherin at a juxta-membrane site. The complex stabilizes tight junctions. In the cell, p120 catenin localized to the E-cadherin/catenins cell adhesion complex, directly associates with cytoplasmic C-terminus of E-cadherin and may similarly interact with other cadherins. p120 is a proliferation-associated nucleolar protein found in most human malignant tumors, but not in resting normal cells. In colorectal cancer the altered localization of p120 catenin corresponds with loss of cytoplasmic localization of E-cadherin. Studies have shown accurate categorization of ductal vs. lobular neoplasia in the breast was achieved with p120 staining. p120 expression further clarifies the separation of low-grade ductal carcinoma in situ from lobular neoplasia. Studies also have shown that altered expression of p120 catenin antibody predicts poor outcome in invasive breast cancer.
There are no reviews yet.